IDYN - ETF AI Analysis
Top Page
iShares International Equity Factor Rotation Active ETF (IDYN)
Rating:65Neutral
Price Target:―
Positive Factors
Strong Leading Holdings
Several of the largest positions, such as ASML, Novartis, and Deutsche Telekom, have shown strong or steady gains, helping support the ETF’s overall results.
Broad International Diversification
The fund spreads its investments across many countries in Europe and Asia, which can reduce the impact of weakness in any single market.
Balanced Sector Mix
Holdings are spread across industrials, financials, health care, communication services, and other sectors, limiting reliance on one part of the economy.
Negative Factors
Recent Short-Term Weakness
The ETF has experienced a weak recent month even though longer-term performance has been more positive, which may signal near-term volatility.
Moderate Expense Ratio
The fund’s fee is higher than many simple index ETFs, which can slightly reduce net returns over time for buy-and-hold investors.
Exposure to Lagging Financial Names
Some financial holdings like Banco Santander and Assicurazioni Generali have been weak, which can drag on performance if this trend continues.
IDYN vs. SPDR S&P 500 ETF (SPY)
AUM102.09M
RegionGlobal Ex-U.S.
Expense Ratio0.45%
Beta0.91
IssueriShares
Inception DateAug 05, 2025
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume5,804
30 Day Avg. Volume8,681
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
34.18Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering179
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IDYN Summary
The iShares International Equity Factor Rotation Active ETF (IDYN) is an actively managed fund that invests in large and mid-sized companies outside the U.S., following a total international market theme rather than a fixed index. It holds well-known global names like ASML Holding and Novartis, and spreads money across many countries such as Japan, the UK, and Germany, as well as some emerging markets. Someone might invest in IDYN for broad international diversification and the potential for growth overseas. A key risk is that international and emerging market stocks can be volatile and may go up or down more than U.S. stocks.
How much will it cost me?This ETF has an expense ratio of 0.45%, which means you’ll pay about $4.50 per year for every $1,000 you invest. That’s higher than the cost of many simple index ETFs because this fund is actively managed and uses a factor-rotation strategy that requires more research and trading.
What would affect this ETF?This ETF could benefit if international economic growth improves, especially in Europe and other markets outside the U.S., boosting industrial, financial, and healthcare companies like ASML, Novartis, and AstraZeneca, and if global stock markets reward the fund’s flexible, factor-based strategy. On the other hand, it could be hurt by slower growth or financial stress in non-U.S. economies, rising interest rates that pressure banks and utilities, energy or regulatory shocks affecting companies like Enel and Siemens Energy, or if its active rotation strategy picks factors that fall out of favor.
IDYN Top 10 Holdings
IDYN’s story is driven by a few standout international names: ASML is doing the heavy lifting, with its rising share price giving the fund a strong semiconductor tailwind, while Siemens Energy and Japan’s Fujikura are also powering ahead and adding spark from the industrial side. On the flip side, AstraZeneca and Deutsche Telekom have been lagging, acting like a bit of sand in the fund’s gears, with Novartis more steady than exciting. Overall, the ETF leans toward industrials and financials across Europe and Asia, with no single country calling all the shots.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 4.32% | $4.49M | €575.73B | 130.86% | 76 Outperform | |
| Novartis AG | 2.95% | $3.07M | CHF217.32B | 22.72% | 80 Outperform | |
| AstraZeneca | 2.63% | $2.73M | $279.48B | 23.45% | 80 Outperform | |
| Iberdrola | 1.87% | $1.94M | €133.99B | 24.23% | 67 Neutral | |
| Assicurazioni Generali S.p.A. | 1.81% | $1.88M | €62.74B | 30.15% | 63 Neutral | |
| Banco Santander SA | 1.73% | $1.80M | $177.06B | 47.34% | 72 Outperform | |
| Enel S.p.A. | 1.67% | $1.73M | €97.57B | 21.13% | 67 Neutral | |
| ― | 1.57% | $1.63M | ― | ― | ― | |
| Siemens Energy | 1.46% | $1.52M | €118.14B | 64.86% | 72 Outperform | |
| Vinci SA | 1.41% | $1.47M | €69.02B | -2.29% | 76 Outperform |
IDYN Technical Analysis
Positive
―
Price Trends
30.39
Positive
30.20
Positive
28.70
Positive
Market Momentum
-0.06
Positive
52.96
Neutral
53.86
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDYN, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 30.46, equal to the 50-day MA of 30.39, and equal to the 200-day MA of 28.70, indicating a bullish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 52.96 is Neutral, neither overbought nor oversold. The STOCH value of 53.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDYN.
IDYN Peer Comparison
Comparison Results
Performance Comparison
IDYN
iShares International Equity Factor Rotation Active ETF
30.64
5.11
20.02%
JDVI
John Hancock Disciplined Value International Select ETF
―
―
―
OSEA
Harbor International Compounders ETF
―
―
―
BRIE
MFS Blended Research International Equity ETF
―
―
―
AVDS
Avantis International Small Cap Equity ETF
―
―
―
QLTI
GMO International Quality ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents